美国乳房再造术后阿片类药物处方模式
基于2024年NSQIP数据库12,338例乳房再造患者,70.6%出院时获阿片类药物处方,中位MME为113,续方率仅4.5%;组织扩张器再造的初始处方与续方风险最高。
要点
- 乳房再造术后70.6%患者出院时获阿片处方,中位MME 113。
- 续方率仅4.5%,提示初始处方可能存在过量。
- 组织扩张器再造的初始处方和续方风险显著高于其他术式。
核心结论
- 多数乳房再造术后患者获阿片处方但续方不频繁,可能提示初始处方过量。
研究设计与样本
- 回顾性队列研究,纳入2024年NSQIP数据库中12,338例无术后并发症的成年女性乳房再造患者。
主要发现
- 8712例(70.6%)出院时获阿片处方,最常见为羟考酮5mg每6小时20片。
- 中位MME为113(IQR 80-150),平均MME在即刻自体再造最高(144.0±74.9),延迟直接植入物最低(108.1±53.2)。
- 与即刻组织扩张器再造相比,即刻自体(OR 0.30, 95%CI 0.26-0.36)、延迟自体(OR 0.48, 95%CI 0.42-0.56)和延迟直接植入物(OR 0.84, 95%CI 0.75-0.94)的处方 odds 更低。
- 续方率为4.5%,除延迟组织扩张器再造(OR 0.85, 95%CI 0.56-1.27)外,所有术式续方 odds 均低于即刻组织扩张器再造(p<0.05)。
临床怎么用
- 乳房再造术后可考虑个体化阿片处方,尤其组织扩张器再造需关注续方风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid prescribing practices following breast reconstruction vary considerably among plastic surgeons. We incorporated recently available data from a national surgical database to evaluate opioid prescription rates, patterns, and renewal depending on demographic and surgical factors. METHODS: Adult female patients who underwent breast reconstruction in the 2024 National Surgical Quality Improvement Program (NSQIP) dataset were identified. Patients with postoperative complications were excluded. The main outcome of interest was opioid prescription at discharge. The secondary outcome was prescription renewal. Demographic and clinical predictors were assessed in a multivariable logistic regression model (p<0.05). RESULTS: Among the 12,338 patients included, 8712 (70.6%) were prescribed opioid medications at discharge. The most common prescription was 20 pills of oxycodone 5 mg q6h. The median (IQR) morphine milligram equivalent (MME) was 113 (80-150). Average MME was the highest in immediate autologous reconstruction (144.0±74.9) and lowest in delayed direct-to-implant (DTI) reconstruction (108.1±53.2). When compared to immediate tissue expander (TE) reconstruction, immediate autologous (OR: 0.30, 95% confidence interval [CI]: 0.26-0.36), delayed autologous (OR: 0.48, 95% CI: 0.42-0.56), and delayed DTI (OR: 0.84, 95% CI: 0.75-0.94) predicted lower odds of opioid prescription. The rate of prescription renewal was 4.5%. All reconstructive modalities conferred lower odds of renewal (p<0.05) except delayed TE reconstruction (OR: 0.85, 95% CI: 0.56-1.27) when compared to immediate TE. CONCLUSIONS: Opioid medications are prescribed following most breast reconstruction procedures, but renewal is infrequent (<5%), which may indicate possible initial prescription excess. Among the reconstruction modalities, TE reconstruction was found to be associated with significantly higher odds of initial opioid prescription and subsequent prescription renewal.
引用
- Warner MM, Kim DK, Zhang A, et al. Opioid prescribing patterns for breast reconstruction in the United States. J Plast Reconstr Aesthet Surg. 2026. PMID: 42869866. doi:10.1016/j.bjps.2026.09.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。